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Abstract: Despite decades of exhaustive research on cancer, questions about cancer initiation,
development, recurrence, and metastasis have still not been completely answered. One of the reasons
is the plethora of factors acting simultaneously in a tumour microenvironment, of which not all have
garnered attention. One such factor that has long remained understudied and has only recently
received due attention is the host microbiota. Our sheer-sized microbiota exists in a state of symbiosis
with the body and exerts significant impact on our body’s physiology, ranging from immune-system
development and regulation to neurological and cognitive development. The presence of our
microbiota is integral to our development, but a change in its composition (microbiota dysbiosis) can
often lead to adverse effects, increasing the propensity of serious diseases like cancers. In the present
review, we discuss environmental and genetic factors that cause changes in microbiota composition,
disposing of the host towards cancer, and the molecular mechanisms (such as β-catenin signalling)
and biochemical pathways (like the generation of oncogenic metabolites like N-nitrosamines and
hydrogen sulphide) that the microbiota uses to initiate or accelerate cancers, with emphasis on
gastrointestinal cancers. Moreover, we discuss how microbiota can adversely influence the success
of colorectal-cancer chemotherapy, and its role in tumour metastasis. We also attempted to resolve
conflicting results obtained for the butyrate effect on tumour suppression in the colon, often referred
to as the ‘butyrate paradox’. In addition, we suggest the development of microbiota-based biomarkers
for early cancer diagnosis, and a few target molecules of which the inhibition can increase the overall
chances of cancer cure.
Keywords: microbiota; Wnt-β-catenin signalling; colorectal cancer; Fusobacterium nucleatum; TLRs;
butyrate
1. Introduction
There are about 100 trillion symbiotic microbial cells in the human body [1]. This gene pool of
the host microbiota is referred to as its microbiome and is composed of the bacteriome (bacterial gene
pool), the virome (viral gene pool), and the mycobiome (fungal gene pool) [2]. Our microbiota is
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primarily composed of bacterial cells (~99%). The gut alone has as many bacteria as the total number
of cells in the human body [3,4]. The mechanism by which the host bacteriome triggers, promotes, or
alleviates cancer is subtler than that of viruses, and only partially understood. An insignificant small
number of bacteria may act as a principal carcinogen; one such example is Helicobacter pylori [5].
Humans encounter various microbes at various stages of their life. A neonate first receives its
microbiota from the mother. In this regard, the mode of delivery of the infant (vaginal versus C-section)
also plays a role in shaping its microbiota, as the mode of delivery determines the first exposure and
composition of a neonate’s microbiota [6–10]. The microbiota and the neonate’s immune system,
through intricate interactions, configure each other further in life [11–13]. This is a delicate process
leading to homeostasis.
2. Microbiota and Host Immunity
Epithelial barriers and certain regulatory proteins like immunoglobulin A (IgA) and regenerating
islet-derived 3 gammas (RegIIIγ) play a crucial role in maintaining a healthy symbiotic relationship
between host and its microbiota. RegIIIγ is an antibacterial lectin that forms a physical barrier
between the gut epithelium and the microbiota, and prevents immune reactions and inflammation.
Microbiota-derived products were reported to contribute to steady-state haematopoiesis and
myelopoiesis [14–16]. More factors governing the relationship between microbiota and host immunity
are discussed below.
3. Microbiota Eubiosis: Characteristics and Implications
Microbiota–immune homeostasis is a state called microbiota eubiosis, and the emergent microbiota
is termed as eubiotic microbiota, which confers important benefits related to physical and mental
health, and the development of an individual. The dynamics of microbiota during life mainly depend
upon the host’s genetics [17,18], environment, lifestyle [19], and dietary habits [20]. Changes in any
of these factors can profoundly alter the gut microbiota. A negative alteration in the gut microbiota
that increases the host’s propensity towards diseases is termed as microbiota dysbiosis [21]. This
dysbiosed microbiota breaks down the delicate homeostasis that existed between eubiotic commensals
and immune system. These events can align the cells and tissue towards inflammation, resulting in
long-term consequences, such as inflammatory bowel disease (IBD) or accelerated tumourigenesis in
cancer patients.
Major factors that lead to microbiota dysbiosis include the early exposure to antibiotics in life,
or the too-frequent use of broad-spectrum antibiotics [22–24], unhealthy habits like alcoholism and
smoking [25], excessive consumption of a modern high-fat and high-protein and low-fibre diet
(referred to as the westernised diet), and genetic mutations in regulatory genes such as sirtuins [26],
nucleotide-binding oligomerisation-domain (NLRP) genes [27], mucin 2 [28–30], and lipocalin 2
(Lcn2) [31] (Figure 1). Most of these regulatory genes control barriers between microbiota and
host tissue, thus preventing inflammation. These regulatory genes also play a key role in shaping
the composition of the gut microbiota. The gain of function mutation in NLRP3 was reported to
positively contribute to microbiota composition, leading to a microbiota that induces anti-inflammatory
state and prevents colorectal cancer (CRC). Lcn2 deficiency increases iron-bound siderophores,
such as enterobactin, in the intestines that cause an overgrowth of Alistipes spp. that assimilate
siderophore-bound iron for their growth. Alistipes spp., which are prominent carcinogenic bacteria [32],
were proven to induce right-sided tumours in the intestine [31,33,34].
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Table 1. Different pathogenic bacteria/bacterial clades, their possible mode of action, and cancer types with these bacteria. List is not exhaustive, but brings out some
common modes of action by different bacterial clades in pathogenesis of different cancers.
Bacteria/Clade Mode of Action Cancer
Helicobacter pylori Disruption of stomach and colonic epithelial integrity creates a niche in stomach suitable for furtherpathogenic bacterial invasion [40]. Stomach and colorectal.
Fusobacterium nucleatum
Suspension of disintegration of β-catenin signalling, increased expression of TLR4 activation of p21-
activated kinase and cyclin D1 [41], increased inflammatory gene expression, and suppression of
antitumour NKT cells via effector molecules FadA and Fap2 [42,43].
Stomach, colorectal, oral, and lung.
Bacteroides fragilis Reactive-oxygen-species (ROS) generation leading to DNA damage, colon-epithelial-barrierdisruption, and depletion of mucous membrane, causing increased inflammation [44–46]. Stomach, colorectal, and lung.
Pathogenic Escherichia coli Toxin colibactin indirectly induces release of growth factors in tumour microenvironment; cytotoxicnecrotizing factor (CNF)-mediated disruption of host cell DNA repair mechanism [47,48]. Stomach and lung.
Salmonella sp. Stabilises and prevents degradation of β-catenin by deubiquitinase activity of its AvrA protein [49–51]. Stomach, colorectal, gall-bladder, and lung.
Peptostreptococcus anaerobius Increases expression of SREB2 gene via ROS, causing increased cholesterol biosynthesis in colon [52]. Colorectal.
Citrobacter rodentium Loss of cell polarity, depletion of epithelial barrier, and increased inflammation [53]. Colorectal.
Mycobacterium tuberculosis, Streptococcus viridans,
Haemophilus influenza, Streptococcus pnuemoniae,
Staphyloccocus
Involved in various chronic inflammatory lung disorders like asthma, cystic fibrosis, and chronic
obstructive pulmonary disease; potential for accelerating tumourigenesis via inflammatory cytokines
like tumour necrosis factor [54–56].
Lung.
Porphyromonas gingivalis and Aggregatibacter
actinomycetemcomitans
Reach pancreas from oral cavity through blood circulation and act as secondary drivers of cancer;
impair host innate immunity, leading to increased colonisation by other bacteria, leading to chronic
inflammation of pancreas causing accelerated tumourigenesis [57–59].
Pancreatic.
Proteobacteria, Betaproteobacteria, Firmicutes,
Alcaligenaceae, Burkholderiales Alter metabolism and oestrogen recycling, and exert pressure on immune system [38]. Breast.
P. gingivalis and Tannerella forsythia
Cause overexpression of inflammatory cytokines; gingipain K produced by P. gingivalis paralyses
immune cells, and induce indirect overexpression of glucose-transporter (GLUT-1 and GLUT-4) genes
that help in faster tumour-cell proliferation [60–63].
Oesophageal.
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4. Dysbiosed Microbiota as Tumour Promoter
Both in vivo and in vitro studies, as well as xenograft murine models, have brought out some
common mechanisms that a microbiota that has gone astray employs in the pathogenicity of different
kinds of cancer in its host. These mechanisms are summarised in Figure 2 and Table 1. A bacterial
clade that finds a neoplastic environment suitable for its survival can use more than one mechanism at
a time to speed up the process of tumourigenesis. Some bacterial clades are even involved in cancer
metastasis and recurrence after chemotherapy. The major tools and mechanisms that the dysbiosed
microbiota uses are as follows.
4.1. Cyclomodulins
Oncogenic bacterial clades can disrupt cell polarity and cytoskeletal structure, and also tip the
balance between cell proliferation and death. They can achieve this through cyclomodulins, which are
genotoxins or effectors that can modulate the eukaryotic-cell cycle [64].
A common example is the cyclomodulins-mediated activation of the Wnt–β-catenin pathway [65].
Activated β-catenin forms a complex with the Tcf family of transcription factors that can upregulate
the expression of oncogenes like c-myc [66]. Cyclomodulins that promote cell proliferation generally
interact with the Rho family of GTPases such as Gln61, which can then disrupt cytoskeletal structures and
relay mitogenic signals inside the cells [67]. Cytotoxic necrotizing factor (CNF) released by E. coli [47,68]
and Yersinia pseudotuberculosis [69], dermonecrotic toxin by Bordetella sp. [70], Pastreulla multocida toxin
(PMT) [71], and cytotoxin-associated gene A (Cag A) from H. pylori [72] are cyclomodulins that increase
cell proliferation: PMT inhibits apoptosis in tumour cells, Cag A can also cause epithelial-barrier
disruption, and the Bacteroides fragilis toxin indirectly damages DNA by generating reactive oxygen
species (ROS) [44].
4.2. Microbial-Associated Molecular Patterns (MAMPs) and Inflammation
MAMPs are microbe-derived chemical motifs, such as surface molecules and endotoxins. A very
common example of a MAMP is the lipopolysaccharide (LPS) layer of Gram-negative bacteria.
Pattern-recognition receptors (PRRs), especially toll-like receptors (TLRs) like TLR-4 and TLR-5 of
innate immunity, recognise MAMPs and mount a suitable immune response against a microbe.
Members of a dysbiosed microbiota in the tumour microenvironment activate certain TLRs by their
MAMPs. The activated TLRs can elicit an inflammatory response in the region of the tumour via
interleukins such as IL-23, IL-17, IL-18, and IL-6 [73]. These inflammatory interleukins further promote
the growth of tumour cells, inhibit apoptosis, and harm neighbouring normal cells through transcription
factor NF-κB. TLR4 does not only exert a proinflammatory response; rather, in an underacetylated
condition, LPS molecules from predominant gut species like Bacteroides on interaction with TLR4 mostly
exert an immunoinhibitory effect [74]. For better understanding of the relationship of microbiota and
host immunity, please see the recent review by Giuffre et al. and references therein [74].
4.3. Oncogenic Microbial Metabolites
Oral and gut microbiota play a significant role in host metabolism. A dysbiosed microbiota
can disrupt natural host metabolism and physiology, and lead to the production of metabolites that
drive tumourigenesis and impair antitumour immunity. An example of this is the conversion of
primary into secondary bile acids such as deoxycholic acids by dysbiosed Gram-positive bacterial
strains decreasing natural-killer T (NKT) cell populations and accelerating hepatocellular-carcinoma
(HCC) [74,75] development [76].
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5. Gut Microbiota and Gastrointestinal Cancers: Potential Molecular Mechanisms
Ample studies have established the important role of gut-microbiota dysbiosis in the development
of gastrointestinal-tract cancers. Metagenomics studies revealed that many oral bacteria or oral
bacterial biofilms become associated with gastrointestinal malignancies in the initial stages, and assist
in accelerating tumourigenesis [77]. Fusobacterium nucleatum (Fn) is a Gram-negative, anaerobic, oral
commensal that makes use of the haematogenous route to reach tumour cells in the gut from the
oral cavity. Other common oral bacterial clades found in intestinal malignancies include Prevotella
and Parvimonas.
Inflammatory conditions like IBD, Crohn’s disease [78], colitis, and cancerous genetic mutations
like the adenomatous polyposis coli gene (APCmin/+), mismatch repair gene (Msh2–/–), and B-Raf
proto-oncogene (BRAF) mutations are often associated with pro-oncogenic gut microbiota that may
include bacteria like enterotoxigenic Bacteroides fragilis (ETBF) [45,46] and Fn [79–81].
5.1. Cancer Initiation and Progression in Stomach
Unlike the intestines, our stomach is considered sterile due to its highly acidic environment.
Bacteria in the stomach cannot remain there and are in a passage from mouth to intestine along
with food [82]. However, the Gram-negative H. pylori penetrates the gastric mucosa and establishes
itself there. It then increases the pH of its environment by secreting urease that leads to decreased
acid secretion and achlorhydria, changing the gastric microbiota. H. pylori also induces a strong
inflammatory response and releases CagA (120–145 kDa protein) and peptidoglycan into the cellular
environment. CagA on phosphorylation in the gastric mucosa disrupts the cytoskeletal structure and
cell–cell junctions. Peptidoglycan activates the phosphatidylinositol 3-kinase (PI3K-Akt) signalling
pathway, resulting in the inhibition of cell apoptosis and enhanced cellular migration. H. pylori thus
transforms normal gut epithelial cells into malignant cells [83–86].
According to a study on the Taiwanese population [40], the abundance of H. pylori in the
transformed cells is diminished and replaced by other bacteria like Fn, Streptococcus, Prevotella, Veillonella,
Burkholderia, Nitrospirae, Escherichia, and Shigella. which could further drive tumourigenesis [60,61].
Another computational study found that the most common bacterial DNA that is integrated into
transformed cells of gastric adenocarcinomas belongs to Pseudonomas [62]. It can thus be hypothesised
that prolonged H. pylori infection could increase the chances of colonisation of other tumour-accelerating
bacteria due to achlorhydria.
5.2. Cancer Initiation and Progression in Intestine
Intestines harbour many symbiotic bacteria like Lactobacillus and Lachnospiraceae. These bacteria
help in proper digestion, producing anti-inflammatory effects and preventing the colonisation of the
intestines by oral bacterial clades. However, studies indicate that the absence of these beneficial bacteria,
and microbiota dysbiosis in the intestine can lead to an imbalance of the immune system, diabetes [63],
obesity [87], IBD, and intestinal cancers. The enumeration of intestinal microbiota dysbiosis, especially
that of the large intestine, can provide us with better insights into the development, metastasis, and
recurrence of colorectal cancer (CRC). The severity of CRC in different patients, which is dependent
on the location of the tumour in the intestines [88] or the resistance intensity to chemotherapy, can
be better determined by understanding host–microbiota interactions in CRC [36,89]. The impact of
different dietary and lifestyle habits on the chances of CRC development in the entire population is
also dependent on intestinal microbiota than any other factor [90,91].
Some of the most important bacteria that play a key role in the pathogenesis of CRC are Fn,
Bacteroides fragilis, and E. coli. A dysbiosed microbiota can accelerate tumourigenesis in the colon by
converting neoplastic polyps into adenomas and adenocarcinomas. This increased fecundity of tumour
polyps is a result of the microbiota’s ability to upregulate oncogenes and elicit inflammation [92–94].
Tumour cells in CRC are uniquely overexpressed on their surface receptors, such as E-cadherin and
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galactose/N-acetylgalactosamine (Gal–GalNAc) lectin. These receptors have an affinity for two virulent
adhesion proteins, FadA and Fap2, present on the surface of Fn.
Fn binds to E-cadherin receptors via FadA and could activate Wnt oncogenes and inflammatory
genes [42]. E-cadherin–FadA interaction leads to the immediate phosphorylation of E-cadherin, and
then to its internalisation into the cytoplasm and the activation of β-catenin signalling. β-catenin
signalling then activates the LEF/TCF, oncogenes Myc and cyclin D1, and NF-κB, the prime driver of
inflammation. Although β-catenin signalling is required for the activation of oncogenes and NF-κB,
E-cadherin–FadA internalisation is mandatory for the activation of inflammatory genes, but not
oncogenes, as shown in Figure 3. This internalisation of E-cadherin and FadA is carried by clathrin,
and inhibition of clathrin leads to failure of activation of inflammatory genes.
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oral carcinoma are unable to adhere and persist in the tumour niche of CRC even though the tumour
microenvironment is also suitable for the growth of P. gingivalis [43].
Besides Fn, E. coli is a common commensal bacterium of the human intestines that prevents
the colonisation of other pathogenic bacteria in the intestine. However, certain strains of E. coli are
themselves pathogenic and referred to as pathobionts that are commonly associated with tumour
cells in CRC; recent studies have confirmed their role not only in CRC acceleration, but also in its
establishment [97]. The general mechanisms by which pathogenic E. coli drives cancers are via toxic
cyclomodulins like CNF, as discussed above, and by disrupting the DNA repair mechanism of the
host cells. The most profound of these toxins is colibactin encoded by the polyketide synthase (pks)
locus of the pks+ E. coli [48,98]. The pks+ E. coli induces cell senescence via colibactin, but, at a low
multiplicity of infection (MOI), this effect can promote tumourigenesis. At an MOI of 20, the pks+
E. coli via colibactin activates c-Myc that, in turn, activates the promoter regions of miRNA 20a-5p.
These miRNAs can cause the SUMOylation of p53 genes (inhibiting p53 activity) and downregulate
the expression of sentrin-specific protease 1 (SENP1). All this leads to the senescence of cells that then
release growth factors, the most important of which is hepatocyte growth factor (HGF), into the tumour
microenvironment, leading to the accelerated growth of neighbouring tumour cells [99]. However,
at a higher MOI of 100, colibactin-induced cellular senescence can completely inhibit tumour-cell
proliferation and reduce their numbers due to cell senescence.
5.2.1. Microbiota-Driven Suppression of Antitumour Immunity
The gut microbiome is not only capable of triggering and accelerating tumourigenesis, but
it can also help a tumour successfully evade an immune response against it. NK cells with other
tumour-infiltrating lymphocytes (TILs) are mainly responsible for destroying tumour cells by identifying
specific ligands through their activating receptors. On the other hand, the activity of these immune
cells is kept in check by various inhibitory receptors on their surface. An example of these receptors
is the T-cell immunoglobulin and ITIM domain (TIGIT) receptor that is expressed on a majority
of TILs, including NK cells and T lymphocytes. Fn, so frequently associated with adenomas and
adenocarcinomas, can dampen this antitumour response of TILs by binding its Fap2 protein to the TIGIT
receptor present on their surface [100]. Fap2 thus plays the dual role of tumour-cell adhesion molecule
and TIL inhibitor via haemagglutination. Some microbial-derived products can be immunosuppressive,
and some can provoke an immune response against cancer, as seen in the case of Coley’s toxins [101].
5.2.2. Microbiota Role in CRC Metastasis and Recurrence
Loss of contact inhibition and disruption of cell–cell adhesion molecules are important
prerequisites for the epithelial-to-mesenchymal transition (EMT) and metastasis of tumour cells.
In altered-microbiota-driven CRC, Fn that is highly prevalent in CRC tissue binds to the E-cadherin
expressed on adenomas and adenocarcinomas, leading to its internalisation into the cytoplasm, and
the activation of the β-catenin complex and inflammatory genes. The E-cadherin/β-catenin complex is
involved in cell adhesion, morphogenesis, polarity, migration, and development. The activation of the
β-catenin complex leads to EMT and the metastasis of various solid tumours. Therefore, Fn-mediated
activation of the β-catenin complex can incline CRC tumour cells towards metastasis.
Fn is one of the primary reasons for CRC metastasis in many patients and it carries itself along
with other oral anaerobes to distant sites to find a new niche. Other oral commensals like Bacteroides,
Salmonella, and Prevotella that are present, along with Fn, in CRC tissue are incapable of tumour-cell
metastasis by themselves, and are therefore dependent on Fn.
In addition to initiating metastasis, a high persistence of Fn was found in malignant cells of
recurrent CRC patients. Drugs like oxaliplatin and 5-fluorouracil (5-FU) combined are one of the
most common chemotherapeutic regimens used for the treatment of CRC. However, a lot of patients
show recurrence after treatment with this regimen due to drug resistance, resulting in a five-year
survival rate of less than 10% in such patients. Fn, even at low MOI, is one of the major factors
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responsible for conferring chemotherapeutic resistance against oxaliplatin and 5-FU by modulating the
autophagy pathway in tumour cells [102]. Fn, via TLR4 and its signalling adapter molecule MyD88,
can suppress the expression of miR18* and miR4802 in the cell. The suppression of these miRNAs
causes upregulation in the expression of two proteins, Unc-51-like autophagy-activating kinase (ULK1)
and autophagy-related 7(ATG7). The activation of the autophagy pathway thus helps tumour cells to
be preserved through all the toxicity and stress inflicted upon them by the chemotherapeutic regimen.
Therefore, adverse alterations in the gut microbiota can not only trigger and accelerate CRC, but also
cause its metastasis and recurrence. One of the ways of reducing tumourigenic microbial load is
by treatment with antibiotics. Metronidazole administration was shown to decrease Fn abundance,
causing a reduction in cell proliferation and tumour load [103].
5.2.3. Dietary Habits, Host–Microbiome Cometabolism, and the Butyrate Paradox
Our normal gut microbiota depends upon the fermentation of the indigestible dietary-fibre
component of our diet for its energy requirements. The symbiotic intestinal microbiota ferments dietary
fibres into short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate, of which butyrate
is the most important [91]. These SCFAs have significant anti-inflammatory and immunomodulatory
functions, and thus protect an individual from CRC [104–106].
Acetate induces IgA activation by interacting with G-protein-coupled (GPR43) receptors present
on adipose tissue in the intestine [107]. IgA plays an integral role in the modulation of gut microbiota
and maintaining microbiota eubiosis by binding to pathogenic bacteria (expressing certain IgA-targeted
epitopes) and suppressing their growth [108–111]. Another study reported that IgA promotes the
symbiosis of beneficial gut bacteria [112]. A decrease in dietary-fibre intake coupled with the increased
consumption of a westernised diet (low-dietary-fibre, and high-protein and high saturated-fat) [113]
leads to a drastic decline in healthy and probiotic gut microbiota, and paves the way for other
opportunistic carcinogenic pathogens [104] such as invasive pks+ E. coli [114]. In a study, less
dietary-fibre consumption was associated with the increased expression of miRNA 17–92a clusters
on colonic-cancer-cell lines. MiRNAs 17–92a are involved in the upregulation of tumour-inducing
genes [115–117].
Butyrate inhibits colonocyte proliferation, and promotes apoptosis by the inhibition of histone
deacteylase [118,119] and the canonical Wnt signalling pathway [120]. Butyrate maintains an
anti-inflammatory state in the colon (via anti-inflammatory cytokines FOXP3 and IL-10) by interacting
with the GPR 41 and GPR 43 receptors [121–123]. Butyrate also regulates CD4+ and CD8+ Treg
cells [124]. CD8+ T cells further mediate the apoptosis of tumours cells by employing IFN-γ and
granzyme-B production [124]. However, not all studies agreed on the tumour-suppressing effect of
butyrate, and some reported the opposite, i.e., butyrate could further promote tumourigenesis in
neoplastic cells. For instance, in an APC and MutS protein homolog 2 (Msh2, a DNA mismatch repair
protein) gene-mutation-driven model of CRC, butyrate accelerated the proliferation of neoplastic
cells [125]; this was termed as the butyrate paradox. In the APC/Msh2 mouse model, there was high
dysregulation of Wnt–β-catenin activity [125]. The intensity of Wnt–β-catenin activity is directly
related to the amount of butyric acid produced by the colonic microbiota. Very high Wnt–β-catenin
activity leads to cell apoptosis. However, a moderate amount of butyrate maintains the Wnt–β-catenin
activity required for cell proliferation [126]. It can thus be hypothesised that, in the model of Belcheva
et al., moderate levels of butyrate production coupled with dysregulated β-catenin lead to enhanced
tumour-cell proliferation (Figure 4).
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colonic inflammation and cancer. 
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Figure 4. Butyrate paradox. (a) Effect of different levels of butyrate in Azoxymethane/Dextran sodium
sulphate (AOM/DSS) treated mouse model. DSS is a colon epithelium disrupting agent that can induce
colitis and AOM is a genotoxin. Combined AOM and DSS treatment in mice creates a model similar to
that of human CRC to study the effects of inflammation and underlying genetic mutations in colon
epithelium cells on microbiota dysbiosis and tumourigenesis [127]; (b) effect of moderate levels of
butyrate on adenomatous polyposis coli (APC)/ MutS protein homolog 2 (Msh2) mouse model.
Hydrogen sulphide (H2S) produced in the gut can cause colonic inflammation and cancers [128].
H2S in the colon can in uce tumourigenesis by ca sing DNA damage and the inhibitio of butyrogenesis.
The major source of H2S in the gut is sulphur-reducing δ-proteobacteria th t include Desulfovibrio
and Desulfobulbus. B cteria capable of the des lfhydration of cysteine and methionine, such as H.
pylori, E. coli, and Enterococci, and assimilatory sulp ite-reducing γ-proteobacteria such as Klebsiella,
Firmicutes, and Bacteriodites are also some of other sources of H2S in the gut. A high abundance
of these H2S-producing bacteria in the gut can dispose of the h st towards H2S-mediated colonic
inflammati n and cancer.
An excessive amount of proteins in the diet can lead to malabsorption of proteins in the small
intestine, which can lead to an excess of protein seepage into the large intestine, where the gut
microbiota of the large intestine converts these proteins into metabolites such as N-nitrosamines,
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ammonia, and hydrogen sulphide, which are all potentially carcinogenic [129]. Lactobacillus spp. can
detoxify ammonia generated in the large intestine [130], but dysbiosis leading to a decreased abundance
of Lactobacillus can increase CRC risk due to ammonia.
6. Conclusions
All recent studies now convincingly put Fusobacterium nucleatum on equal stature to the already
infamous Helicobacter pylori for its role in cancer. Future research must now discover more such culprits
from our oral and gut microbiota. Moreover, we need to focus on mitigating the impact of microbiota
on cancer causation, acceleration, metastasis, and failure to chemotherapy through the development of
targeted drug-delivery options. Some of the targets for such an approach can be β-catenin molecules
in tumour cells, IL-6, and related TLRs in areas of severe inflammation and microbiota dysbiosis in
the body; molecules like E-cadherin and Gal–GalNac that are overexpressed on tumour cells and
act as binding sites for bacteria or their effector molecules; and miRNAs involved in the autophagy
of tumour cells and their increased proliferation. Another area of extensive research is to develop
microbiota-based biomarkers for the early diagnosis of cancers. This is based on the fact that early
stages of cancer development and progression are accompanied by specific changes in microbiota
populations (as certain operational taxonomic units increase or diminish as they elicit an altered
immune response, increased oxidative stress, and changes in cometabolism). Quantitative assessment
of specific microbial products (colibactin, AvrA, etc.) from cells/tissue or oncogenic cometabolites
from faecal samples can act as biomarkers for cancer diagnostics. These biomarkers should not only
be a determinant of current microbiota status, but should also be able to indicate relative changes in
microbiota populations over time. RT–PCR-based analysis of microbiota populations, DNA biosensors
strips, ELISA-based or faecal immunochemical test-based technologies can be developed to monitor
changes in biomarkers in specific cells/tissue, and blood or stool samples. Continuous monitoring
of changes in microbiota profiles may thus help in the identification of dysplasia. A more complete
and holistic approach towards treating diseases as severe as cancer must include host–microbiota
interactions as important screening and cure factors.
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